Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.73 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.73 |
| ▸ | NAMPT | P43490 | 2/20 | 0.72 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.71 |
| ▸ | NPC1 | O15118 | 4/20 | 0.67 |
| ▸ | RAB9A | P51151 | 4/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.67 |
| ▸ | TP53 | P04637 | 1/20 | 0.67 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.64 |
| ▸ | MEN1 | O00255 | 3/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | GFER | P55789 | 1/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.63 |
| ▸ | APP | P05067 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nicotinanilide SCHEMBL352439 | 0.88 | LMNA (0.83) | ROCK2ROCK1NAMPTLMNAHIF1A | |
| Nicotinanilide SCHEMBL29067673 | 0.88 | LMNA (0.83) | ROCK2ROCK1NAMPTLMNAHIF1A | |
| Nicotinanilide SCHEMBL8155304 | 0.87 | LMNA (0.81) | ROCK2ROCK1NAMPTLMNAHIF1A | |
| SCHEMBL29596226 | 0.86 | ROCK2 (0.71) | ROCK2ROCK1NAMPTLMNAHIF1A | |
| SCHEMBL6602214 | 0.86 | ROCK2 (0.71) | ROCK2ROCK1NAMPTLMNAHIF1A | |
| SCHEMBL21391312 | 0.86 | ROCK2 (0.71) | ROCK2ROCK1NAMPTLMNAHIF1A | |
| SCHEMBL3093627 | 0.86 | ROCK2 (0.71) | ROCK2ROCK1NAMPTLMNAHIF1A | |
| SCHEMBL5384036 | 0.85 | ROCK2 (0.76) | ROCK2ROCK1NAMPTLMNAHIF1A | |
| SCHEMBL3642636 | 0.85 | NAMPT (0.81) | NAMPTLMNAHIF1ANPC1RAB9A | |
| SCHEMBL14880208 | 0.85 | ROCK2 (1.00) | ROCK2ROCK1NAMPTLMNAHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016102969-A1 | INHIBITION OF HAIR GROWTH | THE UNIVERSITY OF MANCHESTER (GB) | 2016-06-30 | — | — | WO | claimed |
| US-20220324899-A1 | COMPOUNDS AND COMPOSITIONS FOR DIFFERENTIAL MODULATION OF NICOTINAMIDE ADENINE DINUCLEOTIDE | METRO INTERNATIONAL BIOTECH, LLC | 2022-10-13 | — | — | US | disclosed |
| EP-4013766-A1 | COMPOUNDS AND COMPOSITIONS FOR DIFFERENTIAL MODULATION OF NICOTINAMIDE ADENINE DINUCLEOTIDE | Metro International Biotech, LLC (US) | 2022-06-22 | — | — | EP | disclosed |
| US-20210170033-A1 | NOVEL CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | SANOFI (FR) | 2021-06-10 | — | — | US | disclosed |
| WO-2021030551-A1 | COMPOUNDS AND COMPOSITIONS FOR DIFFERENTIAL MODULATION OF NICOTINAMIDE ADENINE DINUCLEOTIDE | METRO INTERNATIONAL BIOTECH, LLC (US) | 2021-02-18 | — | — | WO | disclosed |
| US-20170152443-A1 | LIQUID CRYSTAL ALIGNMENT AGENT, LIQUID CRYSTAL ALIGNMENT FILM, AND LIQUID CRYSTAL DISPLAY ELEMENT | CHI MEI CORPORATION (TW) | 2017-06-01 | — | — | US | disclosed |
| US-20170152443-A1 | LIQUID CRYSTAL ALIGNMENT AGENT, LIQUID CRYSTAL ALIGNMENT FILM, AND LIQUID CRYSTAL DISPLAY ELEMENT | CHI MEI CORPORATION (TW) | 2017-06-01 | — | — | US | disclosed |
| WO-2016102969-A1 | INHIBITION OF HAIR GROWTH | THE UNIVERSITY OF MANCHESTER (GB) | 2016-06-30 | — | — | WO | disclosed |
| US-5869483-A | KIDNEY DISEASES | AMERICAN CYANAMID COMPANY (US) | 1999-02-09 | — | — | US | disclosed |
| EP-0640592-B1 | N-acylated tricyclic azaheterorings useful as vasopressin antagonists | AMERICAN CYANAMID CO (US) | 1998-12-30 | — | — | EP | disclosed |
| US-5834461-A | TREATING CONGESTIVE HEART FAILURE | AMERICAN CYANAMID COMPANY (US) | 1998-11-10 | — | — | US | disclosed |
| US-5786353-A | Tricyclic benzazepine vasopressin antagonists | AMERICAN CYANAMID COMPANY (US) | 1998-07-28 | — | — | US | disclosed |
| US-5760031-A | KIDNEY DISEASES | AMERICAN CYANAMID COMPANY (US) | 1998-06-02 | — | — | US | disclosed |
| US-5747487-A | N-(4-((4,5-DIHYDRO-6H-THIAZOL(5,4-D)(1)BENZAZEPIN-6-YL) -CARBONYL)PHENYL)BENZAMIDES; DISEASES CHARATERIZED BY EXCESS RENAL ABSORPTION OF WATER, E.G. CONGESTIVE HEART DISEASE, HYERTENSION; OXYTOCIN ANTAGONISTS | AMERICAN CYANAMID COMPANY (US) | 1998-05-05 | — | — | US | disclosed |
| US-5739128-A | ADMINISTERING FOR TREATMENT OF DISEASES CHARACTERIZED BY EXCESS RENAL REABSORPTION OF WATER | AMERICAN CYANAMID COMPANY (US) | 1998-04-14 | — | — | US | disclosed |
| US-5736538-A | TREATS IN MAMMAL THE DISEASE CHARACTERIZED BY EXCESS RENAL REABSORPTION OF WATER, IS CONGESTIVE HEART FAILURE, NEPHROTIC SYNDROME, HYPONATREMIA, CORONARY AND RENAL VASOSPASM, CARDIAC ISCHEMIA, LIVER CIRRHOSIS AND BRAIN EDEMA | AMERICAN CYANAMID COMPANY (US) | 1998-04-07 | — | — | US | disclosed |
| US-5693635-A | TREATMENT OF DISEASES CHARACTERIZED BY EXCESS RENAL ABSORPTION OF WATER; CONGESTIVE HEART FAILURE, NEPHROTIC SYNDROME | AMERICAN CYANAMID COMPANY (US) | 1997-12-02 | — | — | US | disclosed |
| US-5686445-A | Pyridobenzoxazepine and pyridobenzothiazepine vasopressin antagonists | AMERICAN CYANAMID COMPANY (US) | 1997-11-11 | — | — | US | disclosed |
| US-5512563-A | TREATING DISEASES CAUSED BY EXCESS RENAL REABSORPTION OF WATER | AMERICAN CYANAMID COMPANY (US) | 1996-04-30 | — | — | US | disclosed |
| EP-0640592-A1 | N-acylated tricyclic azaheterorings useful as vasopressin antagonists | AMERICAN CYANAMID COMPANY (US) | 1995-03-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210170033-A1 | NOVEL CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | GPR119, SLC2A8, SLC2A4 | ROCK2 4296/4885ROCK1 4365/4885NAMPT 1500/4885 |
| US-20220324899-A1 | COMPOUNDS AND COMPOSITIONS FOR DIFFERENTIAL MODULATION OF NICOTINAMIDE ADENINE DINUCLEOTIDE | NQO1, NAMPT, NADK | ROCK2 1398/4885ROCK1 1062/4885NAMPT 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.